Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 19 2013
Print RSS Feed

Breaking News

Related Searches:
Hovione

December 30, 2008
Roger Viney, Ph.D. has been named director of sales & marketing Europe and Asia for Hovione. Thomas Eisele, Ph.D. has been named general manager R&D at the company and Steve Beagle has been named director of sales & marketing, North Ameri…  Read More »
King Starts Phase II for Pain Drug

December 30, 2008
King Pharmaceuticals has initiated the Phase II trial evaluating the efficacy and safety of T-62, an investigational drug for the treatment of neuropathic pain. Dr. Eric Carter, chief science officer of King, remarked, “T-62, a new chemical…  Read More »
Onyx Pharmaceuticals

December 30, 2008
Matthew K. Fust has been named executive vice president and chief financial officer of Onyx Pharmaceuticals. Mr. Fust will serve as Onyx's principal financial and accounting officer and report to N. Anthony Coles, M.D., the company's president and ch…  Read More »
Actavis Reaches Consent Degree Over NJ Facilities

December 30, 2008
Actavis Inc. has reached agreement with the FDA on a Consent Decree of Permanent Injunction the company’s Actavis Totowa LLC subsidiary. This agreement, in effect, settles the issues identified by the Department of Justice in its previously fil…  Read More »
Savient BLA Gets Priority Review

December 30, 2008
The FDA has accepted Savient Pharmaceuticals' BLA for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted Savient's BLA a priority review status which accelerates the review period to six months. This…  Read More »
GSK, Archemix Form Strategic Aptamers Alliance

December 23, 2008
GlaxoSmithKline and Archemix Corp. have entered a worldwide strategic alliance to discover, develop and commercialize aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Aptamers are synth…  Read More »
Pierre Fabre, Forest Labs Enter Depression Drug Pact

December 23, 2008
Forest Laboratories, Inc. and Pierre Fabre Medicament have entered into a definitive collaboration agreement to develop and commercialize F2695 in the U.S. and Canada. F2695 is a selective norepinephrine and serotonin reuptake inhibitor being develop…  Read More »
Kendle

December 23, 2008
Kerri Schoedel, Ph.D. has been promoted to scientific director, clinical pharmacology for Kendle's Early Stage unit in Toronto. Dr. Schoedel will provide overall scientific direction and leadership to the clinical pharmacology group, as well as lead…  Read More »
Sanofi, Novozymes in Antibiotic Pact

December 22, 2008
Sanofi-Aventis and Novozymes have signed a development and marketing collaboration for a potential new antibiotic. The drug candidate is an antimicrobial peptide named Plectasin NZ2114 that targets the treatment of severe infections, such as pneumoni…  Read More »
AZ, MAP Collaborate on Asthma

December 22, 2008
AstraZeneca and MAP Pharmaceuticals have formed an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharma…  Read More »
Amgen Submits Denosumab BLA

December 22, 2008
Amgen has submitted a Biologics License Application (BLA) with the FDA for denosumab, an investigational RANK Ligand inhibitor. Amgen is seeking approval for treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and pr…  Read More »
PharmaNet Looks for Buyer

December 19, 2008
PharmaNet Development Group is working with a financial advisor to pursue strategic alternatives, including the potential sale of the company. “The Board of Directors and management believe that pursuing strategic alternatives will maximize sha…  Read More »
Oncothyreon Restructures, Sells Stimuvax Site

December 19, 2008
Oncothyreon Inc. has announced plans to restructure and focus on development of two compounds, PX-478 and PX-866. PX-478 is an inhibitor of hypoxia inducible factor-1 alpha that is currently in a Phase I trial for advanced metastatic cancer and lymph…  Read More »
Wyeth Acquires Thiakis

December 18, 2008
Wyeth has acquired Thiakis Limited, a privately held biotechnology company based in the United Kingdom. Thiakis' lead product candidate, TKS1225, is being studied for the treatment of medical obesity and other co-morbidities. TKS1225 and related comp…  Read More »
GSK Licenses PER.C6 from DSM, Crucell

December 18, 2008
GlaxoSmithKline has signed a license agreement with DSM Biologics and Crucell, allowing GSK to research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed. "We are very pleased to enter into this…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: